NovoCure CFO sells 7,343 shares to cover vesting taxes

Available on EDGAR 11/12/2026 - 04:09 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:07 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

NovoCure Ltd (NVCR) Chief Financial Officer Christoph Brackmann sold 7,343 ordinary shares on November 9, 2026, at a weighted average price of $12.862 per share. The trades ranged from $12.61 to $13.11 per share.

The sale was required under the issuer’s award agreement to cover tax withholding from restricted stock unit vesting and was not discretionary. Brackmann directly held 175,499 shares after the transaction; no Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Seller: 7,343 shares

Net Sell 1 txn

Insider Brackmann Christoph

Role Chief Financial Officer

Sold 7,343 shs ($94K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	7,343	$12.862	$94K

Holdings After Transaction: Ordinary Shares — 175,499 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
2. F2. This transaction was executed in multiple trades at prices ranging from $12.61 USD to $13.11 USD; the price reported above reflects the weighted average sale price.

Key Figures

Shares sold: 7,343 ordinary shares Weighted average sale price: $12.862 per share Trade price range: $12.61–$13.11 per share +1 more

4 metrics

Shares sold 7,343 ordinary shares November 9, 2026; tax-withholding sale tied to restricted stock unit vesting

Weighted average sale price $12.862 per share Multiple trades on November 9, 2026

Trade price range $12.61–$13.11 per share Multiple trades on November 9, 2026

Direct shares held after transaction 175,499 ordinary shares Christoph Brackmann’s reported direct holdings after the sale

Key Terms

Restricted Stock Units, sell to cover, weighted average sale price

3 terms

Restricted Stock Units financial

"vesting of Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"a “sell to cover” transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average sale price financial

"reflects the weighted average sale price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NVCR shares did CFO Christoph Brackmann sell, and at what price?

Christoph Brackmann sold 7,343 ordinary shares on November 9, 2026, at a weighted average price of $12.862 per share. The trades ranged from $12.61 to $13.11 per share.

Why did Christoph Brackmann sell NVCR shares?

The sale was required by NovoCure’s award agreement to fund tax withholding obligations connected with the vesting of Restricted Stock Units; it did not represent a discretionary trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brackmann Christoph

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/09/2026		S		7,343(1)	D	$12.862(2)	175,499	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $12.61 USD to $13.11 USD; the price reported above reflects the weighted average sale price.

Remarks:

	Steven Robbins, as attorney in fact for Brackmann, Christoph	11/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)